NICE: NeuroImaging in Cessation Education
10 de agosto de 2020 atualizado por: Yale University
Effect of Showing Stroke Neuroimaging to Patients in Setting of Smoking Cessation Education on Smoking Cessation Rates in Patients With New Stroke.
The investigators aim to examine the effect on smoking cessation rate by showing stroke patients who are active smokers images of their strokes.
Visão geral do estudo
Status
Rescindido
Condições
Intervenção / Tratamento
Descrição detalhada
The investigators hypothesize that showing actual images of a patient's stroke to the participant on either brain CT or MRI will be a similarly easy to understand quantification of damage done to the participant's body.
Given the link between smoking and stroke risk, the investigators believe that providing this imaging in addition to standard smoking cessation education may improve rates of smoking cessation after stroke.
If this proves true, addition of a patient's neuroimaging to standard post-stroke smoking cessation education would be an easy method to improve smoking cessation rates in stroke patients, at minimal cost.
Tipo de estudo
Intervencional
Inscrição (Real)
20
Estágio
- Não aplicável
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
18 anos e mais velhos (Adulto, Adulto mais velho)
Aceita Voluntários Saudáveis
Não
Gêneros Elegíveis para o Estudo
Tudo
Descrição
Inclusion Criteria:
- Age ≥18
- Active smoker, as defined: at least 100 cigarettes in their entire life, must have smoked cigarette at least once in 4 days prior to onset of stroke
- Primary ischemic or hemorrhagic stroke identified on neuroimaging (MRI DWI/ADC or CT of brain)
- Onset of stroke symptoms within 30 days to time of recruitment
- Capacity to comprehend counseling data: Each participant will be given a cognitive screening test to assess the ability to comprehend and accurately answer the medical history questionnaire (MMSE). If the participant fails this test (score < 23), they will be excluded.
- Patients discharged home or short term rehab with expectation of returning home within the study period
Exclusion Criteria:
- Patients whose stroke deficits clinically prevent them from reasonably being physically able to continue to smoke, such as bilateral upper extremity paresis, tracheostomy, GCS ≥9
- Patients with sensory aphasia that impairs comprehension
- Subarachnoid hemorrhage
- Transient ischemic attack
- Other cause of cerebral ischemia or hemorrhage not defined as primary ischemic or hemorrhagic stroke (i.e. hemorrhagic metastases)
- Patients whose stroke symptoms started >30 days from time of enrollment
- Patients discharged to acute rehab, long term acute care hospital or hospice who are unlikely to have access to cigarettes
- Patients unable to complete cognitive screening test for whom an appropriate proxy does not exist
- Patients who do not speak fluent English (given that the study largely revolves around oral education on smoking cessation, clear communication between participant and coordinator must be possible)
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Triplo
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: Standardized smoking cessation counseling
Standardized smoking cessation counseling will be provided at the participant's initial interview.
Participants will be provided pamphlets from the National Stroke Association and the American Heart Association regarding risk factor reduction.
Packets will include general information on risks associated with smoking along with the benefits of cessation, and methods to quit.
Pamphlets will include Life's Simple 7 (American Heart Association, 2014) and Be Smoke Free: Facts about Smoking and Stroke Risk (National Stroke Association, 2009).
Counseling will be scripted and standardized to ensure similar language with all participants.
|
Standardized smoking cessation counseling will be provided at their initial interview.
They will be provided pamphlets from the National Stroke Association and the American Heart Association regarding risk factor reduction.
Packets will include general information on risks associated with smoking along with the benefits of cessation, and methods to quit.
Pamphlets will include Life's Simple 7 (American Heart Association, 2014) and Be Smoke Free: Facts about Smoking and Stroke Risk (National Stroke Association, 2009).
Counseling will be scripted and standardized to ensure similar language with all participants.
|
|
Experimental: Neuroimages of stroke
Participants in the intervention group will undergo standardized smoking cessation counseling (as offered to the active comparator group) and will also be shown computer images of head CT or brain MRI (DWI/FLAIR series) of their strokes.
Basic orientation to neuroimaging (laterality, positioning, parts of the brain) will be provided first, and then the image of the stroke itself will be reviewed.
Participants will be provided with a paper copy of the slice demonstrating the largest volume of stroke to keep.
In comparison, participants will also be shown images of a normal healthy, and images of a patient with recurrent strokes due to smoking.
Participants will be told that smoking cessation would help to prevent additional stroke, but that it would not repair the damage already done, as visualized on the neuroimaging.
|
Participants in the intervention group will be shown computer images of head CT or brain MRI (DWI/FLAIR series) of their strokes.
Basic orientation to neuroimaging (laterality, positioning, parts of the brain) will be provided first, and then the image of the stroke itself will be reviewed.
Participants will be provided with a paper copy of the slice demonstrating the largest volume of stroke to keep.
In comparison, patients will also be shown images of a normal healthy, and images of a patient with recurrent strokes due to smoking.
Patients will be told that smoking cessation would help to prevent additional stroke, but that it would not repair the damage already done, as visualized on the neuroimaging.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
cessation of smoking measured by self-report collected during follow-up phone interviews.
Prazo: 30 day follow-up visit
|
30 day and 90 day post-stroke phone interviews will be by a blinded APRN.
During these interviews, patients will be asked their smoking status.
If they are still smoking, they will be asked how much they are still smoking,
|
30 day follow-up visit
|
|
cessation of smoking measured by self-report collected during follow-up phone interviews.
Prazo: 90 day follow-up visit
|
30 day and 90 day post-stroke phone interviews will be by a blinded APRN.
During these interviews, patients will be asked their smoking status.
If they are still smoking, they will be asked how much they are still smoking,
|
90 day follow-up visit
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
number of cigarettes smoked per day measured by self-report collected during follow-up phone interviews.
Prazo: 30 day follow-up visit
|
30 day and 90 day post-stroke phone interviews will be by a blinded APRN.
During these interviews, patients will be asked their smoking status.
If they are still smoking, they will be asked how much they are still smoking,
|
30 day follow-up visit
|
|
number of cigarettes smoked per day measured by self-report collected during follow-up phone interviews.
Prazo: 90 day follow-up visit
|
30 day and 90 day post-stroke phone interviews will be by a blinded APRN.
During these interviews, patients will be asked their smoking status.
If they are still smoking, they will be asked how much they are still smoking.
|
90 day follow-up visit
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Investigadores
- Investigador principal: Hardik Amin, MD, Yale University
Publicações e links úteis
A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Real)
1 de janeiro de 2017
Conclusão Primária (Real)
1 de julho de 2020
Conclusão do estudo (Real)
1 de julho de 2020
Datas de inscrição no estudo
Enviado pela primeira vez
10 de maio de 2016
Enviado pela primeira vez que atendeu aos critérios de CQ
10 de maio de 2016
Primeira postagem (Estimativa)
12 de maio de 2016
Atualizações de registro de estudo
Última Atualização Postada (Real)
12 de agosto de 2020
Última atualização enviada que atendeu aos critérios de controle de qualidade
10 de agosto de 2020
Última verificação
1 de junho de 2019
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 1606017908
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Não
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Não
produto fabricado e exportado dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .